Back to Search
Start Over
Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia.
- Source :
- Hematology Reports; Jun2024, Vol. 16 Issue 2, p270-282, 13p
- Publication Year :
- 2024
-
Abstract
- The treatment landscape of chronic lymphocytic leukemia (CLL), the most frequent leukemia in adults, is constantly changing. CLL patients can be divided into three risk categories, based on their IGHV mutational status and the occurrence of TP53 disruption and/or complex karyotype. For the first-line treatment of low- and intermediate-risk CLL, both the BCL2 inhibitor venetoclax plus obinutuzumab and the second generation BTK inhibitors (BTKi), namely acalabrutinib and zanubrutinib, are valuable and effective options. Conversely, venetoclax-based fixed duration therapies have not shown remarkable results in high-risk CLL patients, while continuous treatment with acalabrutinib and zanubrutinib displayed favorable outcomes, similar to those obtained in TP53 wild-type patients. The development of acquired resistance to pathway inhibitors is still a clinical challenge, and the optimal treatment sequencing of relapsed/refractory CLL is not completely established. Covalent BTKi-refractory patients should be treated with venetoclax plus rituximab, whereas venetoclax-refractory CLL may be treated with second generation BTKi in the case of early relapse, while venetoclax plus rituximab might be used if late relapse has occurred. On these grounds, here we provide an overview of the current state-of-the-art therapeutic algorithms for treatment-naïve patients, as well as for relapsed/refractory disease. [ABSTRACT FROM AUTHOR]
- Subjects :
- CHRONIC lymphocytic leukemia
VENETOCLAX
TREATMENT duration
Subjects
Details
- Language :
- English
- ISSN :
- 20388322
- Volume :
- 16
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Hematology Reports
- Publication Type :
- Academic Journal
- Accession number :
- 178185552
- Full Text :
- https://doi.org/10.3390/hematolrep16020027